![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Metabolism, Excretion, and Mass Balance of the HIV Integrase Inhibitor, Cabotegravir (GSK1265744) in Humans
|
|
|
Reported by Jules Levin
ICAAC - 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC
A Culp,1 G Bowers,1 E Gould,1 S Ford,1 Y Lou,1 R Pan,2 D Margolis,1 S Piscitelli1
1GlaxoSmithKline, Research Triangle Park, NC; 2GlaxoSmithKline, Collegeville, PA
ICAAC: Cabotegravir Injected Every 1, 2, or 3 Months Yields Adequate Troughs in Simulation
![ICAAC1.gif](../images/091014/091014-5/ICAAC1.gif)
![ICAAC2.gif](../images/091014/091014-5/ICAAC2.gif)
![ICAAC3.gif](../images/091014/091014-5/ICAAC3.gif)
![ICAAC4.gif](../images/091014/091014-5/ICAAC4.gif)
![ICAAC5.gif](../images/091014/091014-5/ICAAC5.gif)
![ICAAC6.gif](../images/091014/091014-5/ICAAC6.gif)
![ICAAC7.gif](../images/091014/091014-5/ICAAC7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|